ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Upgraded by Citigroup

ProQR Therapeutics (NASDAQ:PRQR) was upgraded by investment analysts at Citigroup from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Monday, Marketbeat reports. The firm currently has a $4.00 price objective on the biopharmaceutical company’s stock. Citigroup’s price objective points to a potential upside of 116.22% from the stock’s previous close.

PRQR has been the topic of a number of other research reports. StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. Finally, Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They set an “outperform” rating and a $15.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $9.17.

ProQR Therapeutics Stock Up 2.2 %

PRQR stock opened at $1.85 on Monday. ProQR Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $4.62. The firm’s 50-day simple moving average is $2.31 and its 200 day simple moving average is $2.63. The stock has a market cap of $151.11 million, a PE ratio of -5.78 and a beta of 0.24.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PRQR. Jane Street Group LLC acquired a new position in shares of ProQR Therapeutics in the fourth quarter worth about $30,000. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics in the fourth quarter worth about $32,000. Alpine Global Management LLC acquired a new position in shares of ProQR Therapeutics in the fourth quarter worth about $39,000. Two Sigma Securities LLC acquired a new position in shares of ProQR Therapeutics in the fourth quarter worth about $40,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of ProQR Therapeutics in the fourth quarter worth about $54,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).